TY - JOUR
AU1 - Ugajin, Takashi
AU2 - Hozawa, Atsushi
AU3 - Ohkubo, Takayoshi
AU4 - Asayama, Kei
AU5 - Kikuya, Masahiro
AU6 - Obara, Taku
AU7 - Metoki, Hirohito
AU8 - Hoshi, Haruhisa
AU9 - Hashimoto, Junichiro
AU1 - Totsune, Kazuhito
AU1 - Satoh, Hiroshi
AU1 - Tsuji, Ichiro
AU1 - Imai, Yutaka
AB - Abstract Background White-coat hypertension is a condition characterized by elevated blood pressure (BP) in medical settings combined with normal ambulatory-recorded BP or self-measured BP at home (home BP). However, it is unknown whether this condition represents a transient state in the development of hypertension outside medical settings. Methods We followed up 128 subjects with white-coat hypertension (home BP <135/85 mm Hg and office BP ≥140/90 mm Hg) for 8 years and compared the risk of progression with home hypertension (home BP ≥135/85 mm Hg or start of treatment with antihypertensive medication) with 649 sustained normotensive subjects (home BP <135/85 mm Hg and office BP <140/90 mm Hg) using data from population-based home BP measurement projects in Japan. Results During the 8-year follow-up period, 60 subjects (46.9%) with white-coat hypertension and 144 (22.2%) with sustained normotension progressed to home hypertension. The odds ratio of subjects with white-coat hypertension for progression to home hypertension (adjusted for possible confounding factors) was significantly higher than for subjects with sustained normotension (odds ratio, 2.86; P<.001). This association was observed independent of baseline home BP levels. Conclusion The results from the present 8-year follow-up study demonstrate that white-coat hypertension is a transitional condition to hypertension outside medical settings, suggesting that white-coat hypertension may carry a poor cardiovascular prognosis. White-coat hypertension (WCHT) is a condition characterized by an elevated blood pressure (BP) in a medical setting, combined with normal self-measured or ambulatory-recorded BP. In contrast, sustained hypertension is the presence of an elevated BP regardless of setting or circumstance.1 However, the clinical relevance of WCHT has not been established, and it is controversial whether this condition involves an increased cardiovascular risk. Results from cross-sectional and prospective studies have been contradictory; some had found increased cardiovascular risk in patients with WCHT,2-6 whereas others did not.7-11 It is also unknown whether this condition represents a transient state in the development of hypertension outside medical settings. One small and short-term study12 reported a similar rate of transition to ambulatory hypertension (high BP during ambulatory readings) in subjects with sustained normotension (SNT) (normal BP during office and ambulatory readings) and in subjects with WCHT. Although 2 other studies13,14 reported a high rate for the development of ambulatory hypertension in subjects with WCHT, these studies did not have normotensive control subjects for comparison. Thus, these studies13,14 failed to demonstrate that WCHT was truly a transient state compared with SNT or that it posed a greater risk for progression to hypertension outside medical settings. Self-measurements of BP at home (home BP measurements) make it possible to obtain multiple measurements over a long observation period under relatively controlled conditions.15-17 It has been reported that multiple measurements eliminate observer bias and regression dilution bias; therefore, home BP measurements are more reliable than conventional BP measurements taken in medical settings (office BP).15-17 A few studies have also reported that home BP measurements are better predictors of cerebrovascular and cardiovascular events compared with office BP.18-20 We have followed home BP measurements in a general population sample in Japan since 1987.18,20-22 The present 8-year follow-up study, conducted with 777 normotensive subjects 40 years or older, aims to quantitatively determine the risk of transition to hypertension outside medical settings (at home) in subjects with WCHT and to compare the risk with that in subjects with SNT. Methods Design This study was a part of a longitudinal observational study of subjects who have been participating in a BP measurement project in Ohasama, Japan. The socioeconomic and demographic characteristics of this region and full details of the project have been described elsewhere.18,20-22 The study protocol was approved by the institutional review board of Tohoku University School of Medicine, Sendai, Japan, and by the Department of Health of the Ohasama Town Government. Definition of hypertension Based on several guidelines,15-17 subjects with a home systolic BP of 135 mm Hg or higher and/or a home diastolic BP of 85 mm Hg or higher were classified as having high home BP, while others were classified as having normal home BP. Similarly, those who had office systolic/diastolic BP of 140/90 mm Hg or higher were classified as having high office BP. White-coat hypertension was defined as the occurrence of high office BP and normal home BP. Sustained normotension was defined as the occurrence of normal office BP and normal home BP. Development of home hypertension (hypertension based on home BP measurements) was defined as either progression to high home BP or start of treatment with antihypertensive medication. Study population The selection of subjects for this study has been reported previously.18 Briefly, the subjects were 40 years or older and were residents from 3 of 4 subdivisions of Ohasama (n = 2716). Hospitalized persons (n = 121) and persons with dementia or those who were bedridden (n = 31) were excluded from the study. Individuals who worked out of town (n = 575) were also excluded because the project involved consistent and routine ambulatory BP monitoring. Informed consent to participate in the study was given by 1957 of 1989 eligible individuals. Home BP measurements at baseline were conducted among 1913 subjects who collected their own BP data at least 3 days during the 4-week study period. This criterion was based on our previous observation that the average BP value obtained for the first 3 days was not significantly different from the values obtained for the entire study period.21 We had previously confirmed that these 1913 subjects were a representative sample of the general population.18 In the present analysis, to compare the risk for development of hypertension between WCHT and SNT, we excluded subjects who did not have office BP measured (n = 124) or those who regularly used antihypertensive medication (n = 582). We further excluded 235 subjects who had home hypertension at baseline. Thus, we followed up the remaining 972 participants. Home bp measurements Physicians and public health nurses instructed subjects on how to perform home BP measurements.21 Subjects were asked to measure their BP every morning within 1 hour of waking, while seated and rested for more than 2 minutes, for 4 weeks. The home BP of an individual was defined as the mean of all measurements obtained for that person. The mean (SD [range]) number of baseline home BP measurements was 23.2 (6.8 [3-60]). The clinical utility of those methods of home BP measurements in this project has been previously reported.18,20-22 The same procedure was used for the follow-up home BP measurements. Office bp measurements Annual health check-ups including BP measurements are available to all Japanese citizens 40 years or older once per year. Two consecutive measurements of BP are taken by a nurse or technician, using a semiautomatic device, after the subject has been seated at rest for at least 2 minutes.21 The office (screening) BP was defined as the average of the 2 readings and was obtained in the same year as the initiation of home BP measurement. Bp measuring device Home BP was measured with the HEM401C (Omron Healthcare Co Ltd, Kyoto, Japan), a semiautomatic device, based on the cuff-oscillometric method that generates a digital display of systolic and diastolic BP at baseline. We also used the HEM401C and HEM747ICN devices for measurement at follow-up measurement. The screening BP was measured with an USM-700F (UEDA Electronic Works Co Ltd, Tokyo, Japan), a fully automatic device, based on the Korotkoff sound technique (a microphone method). The circumference of the arm was less than 34 cm in most cases, so we used a standard arm-cuff for both BP measurements. All devices used in this study were validated23,24 and satisfied the criteria of the Association for the Advancement of Medical Instrumentation.25 Data collection and analysis Residential status in the town of Ohasama on October 31, 1999, was confirmed using the residents’ registration cards, which were considered accurate and reliable because they are required for pension and social security benefits in Japan. Information on smoking status, obesity, family history of hypertension, and a history of hypercholesterolemia or diabetes mellitus was obtained from questionnaires sent to each household during the time of home BP measurements and from the medical records at Ohasama Hospital. Ohasama Hospital is the only hospital in the town, and more than 90% of the participants go there for regular checkups. All data are given as mean (SD). The association between the baseline BP and the likelihood of progression to home hypertension was investigated using multiple logistic regression models, adjusted for age, sex, smoking status, obesity (body mass index [BMI; calculated as weight in kilograms divided by the square of height in meters] ≥25), family history of hypertension, and a history of hypercholesterolemia or diabetes mellitus. In all analyses, we treated the subjects with SNT as the reference group. Variables were compared using the unpaired, 2-tailed t test, χ2 test, or analysis of variance, as appropriate. Differences of P<.05 were considered statistically significant. All analyses were conducted using the SAS package (version 8.2; SAS Institute Inc, Cary, NC). Results Follow-up Among the 972 subjects with WCHT or SNT, who did not take antihypertensive medication at the time of baseline survey, 60 died or moved away from the town before the follow-up. Of the remaining 912 subjects, 777 (85%) took part in the follow-up home BP measurements. Mean duration of the period between the baseline and the follow-up home BP measurements was 8.2 (2.0) years. The mean number of follow-up home BP measurements was 23.7 (5.6). Baseline characteristics The baseline characteristics of the subjects in each group are presented in Table 1. The mean (SD) age of the 777 subjects was 56.0 (8.7) years and the proportion of men was 34.0%. Mean (SD) office and home systolic/diastolic BP values were 125.9 (15.8)/72.5 (10.3) mm Hg and 116.0 (9.1)/70.4 (7.2) mm Hg, respectively. Of the 777 subjects, 649 (83.5%) were classified as having SNT, while the remaining 128 (16.5%) were classified as having WCHT. Office and home BP values and the proportion of men were significantly higher in subjects with WCHT than among subjects with SNT. Subjects with WCHT tended to be older and have higher proportions of obesity and a more prominent family history of hypertension than those with SNT. Rate of development of home hypertension Development of home hypertension was defined as either progression to high home BP or the start of treatment with antihypertensive medication. At baseline, 649 subjects had SNT and 128 subjects had WCHT. At the time of follow-up measurements, 144 subjects (22.2%) with SNT and 60 (46.9%) with WCHT developed home hypertension. The rate was significantly higher in subjects with WCHT (P<.001). The significantly higher rate of development of home hypertension in subjects with WCHT was observed for both hypertension defined by a home BP of 135/85 mm Hg or higher (71 [10.9%] of 649 subjects with SNT and 31 [22.7%] of 128 subjects with WCHT [P<.001]) and hypertension defined by the start of treatment with antihypertensive medication (73 [11.2%] of 649 subjects with SNT and 29 [24.2%] of 128 subjects with WCHT [P<.001]). Rate of development of home hypertension by baseline home bp levels Table 2 gives the rates of development of home hypertension, home BP values, and the magnitude of changes for home BP from baseline to follow-up. (Categories were divided according to baseline home systolic and diastolic BP values.) In subjects with WCHT, as well as those with SNT, rates for development of home hypertension showed a significant trend (P<.001), as the baseline home BP values increased across the categories (Table 2). Across a broad range of baseline home BP levels, compared with subjects with SNT, rates of development of home hypertension were higher in most subjects with WCHT (Table 2). In both groups, subjects with a baseline home systolic BP of 108 mm Hg or lower or a diastolic BP of 52 mm Hg or lower had a less than 5% chance of developing home hypertension (Table 2). Similar tendencies were observed regarding the rate for those who developed home hypertension defined by the start of treatment with antihypertensive medication (Table 2). Risk of development of home hypertension The odds ratio (OR) for WCHT to progress to home hypertension, adjusted for other factors, was significantly higher than that of SNT (OR, 2.86; P<.001) (Table 3). In this multivariate model, older age, male sex, and obesity also significantly predicted the development of home hypertension (Table 3). The significant OR of WCHT for progression to home hypertension was similarly observed for both hypertension defined by a home BP of 135/85 mm Hg or higher (OR, 3.09; 95% confidence interval [CI], 1.83-5.23 [P<.001]) and hypertension defined by the start of treatment with antihypertensive medication (OR, 2.71; 95% CI, 1.61-4.56 [P<.001]). Because higher home BP values at baseline were associated with a significantly higher rate of development for home hypertension (Table 2), we adjusted for home systolic/diastolic BP values separately, in addition to the previously mentioned factors. Although higher home BP levels were significantly and independently associated with the risk of home hypertension in the multivariate model (home systolic BP: OR (per 1–mm Hg increase), 1.11; 95% CI, 1.08-1.14 [P<.001]; home diastolic BP: OR (per 1–mm Hg increase), 1.10; 95% CI, 1.07-1.13 [P<.001]), WCHT remained a significant predictor of home hypertension (adjusted home systolic BP: OR, 1.81; 95% CI, 1.16-2.82 [P = .009]; adjusted home diastolic BP: OR, 2.36; 95% CI, 1.55-3.61 [P<.001]). Subgroup analysis of home BP levels at baseline also showed similar results (in subjects with a home BP lower than 125/80 mm Hg26: OR of WCHT, 2.24; 95% CI, 1.25-4.01 [P = .007]; in subjects with a home BP of 125/80 mm Hg or higher and lower than 135/85 mm Hg: OR of WCHT, 1.84; 95% CI, 0.94-3.60 [P = .08]). There was no significant interaction between the subgroup of home BP levels and the presence of WCHT on the risk of development of home hypertension (P = .90). Comment This 8-year follow-up study demonstrated that WCHT was a significant predictor of the development of home hypertension, independent of other confounding factors and baseline home BP levels. The risk of developing home hypertension was consistently higher in subjects with WCHT than in those with SNT, starting at a threshold of 108/58 mm Hg and across a broad range of baseline home BP levels. Our results indicate that WCHT could pose a greater risk for progression to hypertension outside medical settings even if home BP values were within completely normal range. Some studies reported that WCHT is associated with hyperreactivity to stress and higher sympathetic nerve activity.27-29 Because stress has been reported to be an independent risk factor in the development of hypertension,30,31 it is possible that a higher reactivity to stress in medical environments leads to WCHT, which in turn contributes to higher rates of progression to home hypertension in subjects with WCHT. Only 1 study has ever compared the risk of developing hypertension outside medical settings in subjects with WCHT with those with SNT12; results showed that the transition to ambulatory hypertension occurred in a similar way in subjects with SNT and in subjects with WCHT. Those results were inconsistent with our findings; however, in that study the follow-up period was shorter (3.5 years) and the sample size was too small (36 subjects with WCHT and 56 subjects with SNT) to reliably determine the risk of WCHT. In the present study, we followed 649 subjects with SNT and 128 subjects with WCHT for 8-years and found high risk in subjects with WCHT. Although 3 prospective studies reported the prognostic significance of WCHT compared with normotensive control subjects, the results were controversial: 2 studies7,10 with short duration follow-up periods (mean of <5 years) showed similar lower cardiovascular risk for subjects with WCHT compared with normotensive control subjects, but 1 study2 with a longer follow-up (10 years) demonstrated higher risk in subjects with WCHT compared with normotensive controls. In a recent 3-year follow-up study19 of hypertensive patients taking antihypertensive medication, cases of isolated uncontrolled hypertension at the office had a similar risk of cardiovascular events compared with subjects with sustained controlled hypertension. These results and the present 8-year follow-up results suggest that WCHT could potentially represent a cardiovascular risk after 10 or more years. We are pursuing follow-up with research subjects to find the answer to this hypothesis. To define WCHT, BP information obtained outside medical settings (home BP measurements or ambulatory BP monitoring) is necessary. Ambulatory BP monitoring provides a wide variety of BP information outside medical settings, and thus it may offer a more reliable definition of WCHT. However, because ambulatory BP monitoring is not easily achieved in typical clinical settings, it is not necessarily practical as a method to determine WCHT. On the other hand, home BP measurements are now widely recommended by professionals who practice in clinical settings in most developed countries15-17 (in Japan, 30 million devices for self BP measurement at home have been distributed32). For these reasons, we based the definition of WCHT on actual and practical home BP measurements. However, applicability of the present findings to WCHT using a definition based on ambulatory BP remains to be investigated. Development of home hypertension was defined as either progression to high home BP or start of treatment with antihypertensive medication at follow-up. Because subjects with WCHT had a higher office BP level, it is possible that the higher risk of developing hypertension might be attributable to receiving antihypertensive medication according to high office BP levels. However, WCHT showed a significant risk for progression to home hypertension by the definition of home BP levels as well as the start of treatment with antihypertensive medication. Furthermore, the rate of developing home hypertension, defined by the start of treatment with antihypertensive medication, was consistently higher in subjects with WCHT than in those with SNT, across a broad range of baseline home BP levels. Therefore, these findings suggest that WCHT is a transitional condition leading to home hypertension irrespective of high office BP levels. The objective of this study was to investigate home BP, and therefore no office BP data were collected at the time of follow-up. We recommend that the evaluation of subjects with SNT who develop WCHT is a topic for future research. The present 8-year follow-up study based on home BP measurements demonstrated that subjects with WCHT had an approximately 2-fold higher risk of eventually manifesting home hypertension compared with those who had SNT. Although the prognostic significance of WCHT remains unclear, these results suggest that WCHT is not a totally benign condition. Further follow-up studies targeting cardiovascular outcomes are needed to clarify whether WCHT is a potentially dangerous condition. In the meantime, patients with WCHT should be carefully monitored. Correspondence: Yutaka Imai, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan (imai@tinet-i.ne.jp). Accepted for Publication: February 15, 2005. Financial Disclosure: None. Funding/Support: This work was supported by Grants for Scientific Research (12877163, 13470085, 13671095, 15790293, and 14010301) from the Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan; Health Science Research Grants on Health Services (13170201, 13072101, and H12-Medical Care-002) and grant H15-Gan Yobou-039 from the Ministry of Health, Labor, and Welfare, Tokyo; research grants from Junkanki-byo Itaku Kenkyu 11C-5, Tokyo (1999-2000); the Japan Atherosclerosis Prevention Fund, Tokyo (2000-2003); the Uehara Memorial Foundation, Tokyo (2002); a grant from the Japan Cardiovascular Research Foundation, Tokyo (2002); and the Takeda Medical Research Foundation, Osaka, Japan (2003). References 1. Pickering TGJames GDBoddie CHarshfield GABlank SLaragh JH How common is white-coat hypertension. JAMA 1988;259225- 228PubMedGoogle ScholarCrossref 2. Gustavsen PHHoegholm ABang LEKristensen KS White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens 2003;17811- 817PubMedGoogle ScholarCrossref 3. Weber MANeutel JMSmith DHGraettinger WF Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994;902291- 2298PubMedGoogle ScholarCrossref 4. Glen SKElliott HLCurzio JLLees KRReid JL White-coat hypertension as a cause of cardiovascular dysfunction. Lancet 1996;348654- 657PubMedGoogle ScholarCrossref 5. Sega RTrocino GLanzarotti A et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001;1041385- 1392PubMedGoogle ScholarCrossref 6. Björklund KLind LVessby BAndren BLithell H Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002;10663- 68PubMedGoogle ScholarCrossref 7. Verdecchia PPorcellati CSchillaci G et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994;24793- 801PubMedGoogle ScholarCrossref 8. Khattar RSSenior RLahiri A Cardiovascular outcome in white-coat versus sustained mild hypertension. Circulation 1998;981892- 1897PubMedGoogle ScholarCrossref 9. Fagard RHStaessen JAThijs L et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000;1021139- 1144PubMedGoogle ScholarCrossref 10. Kario KShimada KSchwartz JEMatsuo THoshide SPickering TG Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 2001;38238- 245PubMedGoogle ScholarCrossref 11. Celis HStaessen JAThijs L et al. Ambulatory Blood Pressure and Treatment of Hypertension Trial Investigators, Cardiovascular risk in white-coat and sustained hypertensive patients. Blood Press 2002;11352- 356PubMedGoogle ScholarCrossref 12. Polonia JJSantos ARGama GMBasto FBettencourt PMMartins LR Follow-up clinic and ambulatory blood pressure in untreated white-coat hypertensive patients (evaluation after 2-5 years). Blood Press Monit 1997;2289- 295PubMedGoogle Scholar 13. Bidlingmeyer IBurnier MBidlingmeyer MWaeber BBrunner HR Isolated office hypertension: a prehypertensive state? J Hypertens 1996;14327- 332PubMedGoogle ScholarCrossref 14. Colombo FCatarame SCossovich P et al. Isolated office hypertension: are there any markers of future blood pressure status? Blood Press Monit 2000;5249- 254PubMedGoogle ScholarCrossref 15. Pickering TAmerican Society of Hypertension Ad Hoc Panel, Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996;91- 11PubMedGoogle ScholarCrossref 16. O'Brien EAsmar RBeilin L et al. European Society of Hypertension Working Group on Blood Pressure Monitoring, European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21821- 848PubMedGoogle ScholarCrossref 17. Imai YOtsuka KKawano Y et al. Japanese Society of Hypertension, Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003;26771- 782PubMedGoogle ScholarCrossref 18. Ohkubo TImai YTsuji I et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998;16971- 975PubMedGoogle ScholarCrossref 19. Bobrie GChatellier GGenes N et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;2911342- 1349PubMedGoogle ScholarCrossref 20. Ohkubo TAsayama KKikuya M et al. How many times should blood pressure be measured at home for better prediction of stroke risk? 10-year follow-up results from the Ohasama study. J Hypertens 2004;221099- 1104PubMedGoogle ScholarCrossref 21. Imai YSatoh HNagai K et al. Characteristics of a community-based distribution of home blood pressure in Ohasama in northern Japan. J Hypertens 1993;111441- 1449PubMedGoogle ScholarCrossref 22. Hozawa AOhkubo TNagai K et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch Intern Med 2000;1603301- 3306PubMedGoogle ScholarCrossref 23. Imai YAbe KSasaki S et al. Clinical evaluation of semiautomatic devices for home blood pressure measurements: comparison between cuff-oscillometric and microphone methods. J Hypertens 1989;7983- 990PubMedGoogle ScholarCrossref 24. Chonan KKikuya MAraki T et al. Device for the self-measurement of blood pressure that can monitor blood pressure during sleep. Blood Press Monit 2001;6203- 205PubMedGoogle ScholarCrossref 25. Association for the Advancement of Medical Instrumentation, American National Standards for Electronic or Automated Sphygmomanometers (ANSI/AAMI SP 10-1987). Washington, DC Association for the Advancement of Medical Instrumentation1987; 26. Guidelines Subcommittee, 1999 World Health Organization—International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17151- 183PubMedGoogle Scholar 27. Munakata MSaito YNunokawa TIto NFukudo SYoshinaga K Clinical significance of blood pressure response triggered by a doctor's visit in patients with essential hypertension. Hypertens Res 2002;25343- 349PubMedGoogle ScholarCrossref 28. Smith PAGraham LNMackintosh AFStoker JBMary DA Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol 2002;40126- 132PubMedGoogle ScholarCrossref 29. Lantelme PMilon HGharib CGayet CFortrat JO White coat effect and reactivity to stress: cardiovascular and autonomic nervous system responses. Hypertension 1998;311021- 1029PubMedGoogle ScholarCrossref 30. Yan LLLiu KMatthews KADaviglus MLFerguson TFKiefe CI Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA 2003;2902138- 2148PubMedGoogle ScholarCrossref 31. Armario Pdel Rey RHMartin-Baranera MAlmendros MCCeresuela LMPardell H Blood pressure reactivity to mental stress task as a determinant of sustained hypertension after 5 years of follow-up. J Hum Hypertens 2003;17181- 186PubMedGoogle ScholarCrossref 32. Shirasaki OTerada HNiwano K et al. The Japan Home-Health Apparatus Industrial Association: investigation of home-use electronic sphygmomanometers. Blood Press Monit 2001;6303- 307PubMedGoogle ScholarCrossref
TI - White-Coat Hypertension as a Risk Factor for the Development of Home Hypertension: The Ohasama Study
JF - Archives of Internal Medicine
DO - 10.1001/archinte.165.13.1541
DA - 2005-07-11
UR - https://www.deepdyve.com/lp/american-medical-association/white-coat-hypertension-as-a-risk-factor-for-the-development-of-home-BLP0U9U65C
SP - 1541
EP - 1546
VL - 165
IS - 13
DP - DeepDyve
ER -